Search

Displaying results 4101 - 4110 of 10000 in total
  1. Drug

    Dorocubicel

    go.drugbank.com/drugs/DB19448
    Approved

    [L54106] Dorocubicel, as a component of Zemcelpro, was granted conditional marketing authorization in the European Union in August 2025 for use in allogeneic hematopoietic stem cell transplantation … following myeloablative conditioning in adult patients for whom a suitable donor is not available.

  2. Drug

    Sulconazole

    go.drugbank.com/drugs/DB06820
    Approved

    [L44592,L44597] Sulconazole appears to be effective and well-tolerated in the treatment of superficial fungal infections.[A255612] … Sulconazole nitrate, the active ingredient, is an imidazole derivative that inhibits the growth of common pathogenic dermatophytes, making it an effective treatment for tinea cruris and tinea corporis

  3. Drug

    R-30490

    go.drugbank.com/drugs/DB09179
    Experimental

    R-30490 was found to be the most selective agonist for the mu opioid receptor out of all the fentanyl analogues tested, but it has never been introduced for medical use in humans, although the closely … R-30490 is an opioid related to carfentanil used as an animal tranquilizer.

  4. Drug

    Glibornuride

    go.drugbank.com/drugs/DB08962
    ApprovedWithdrawn

    Glibornuride is a sulfonylurea-type anti-diabetic drug.

    Categories: Drugs Used in DiabetesProducts: GLUTRIL 25MG TABLET, 100 ADET
  5. Drug

    Amonafide

    go.drugbank.com/drugs/DB05022
    Investigational

    Amonafide is a substance that is being studied in the treatment of cancer. It belongs to the families of drugs called topoisomerase inhibitors and intercalating agents.

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Ganaxolone

    go.drugbank.com/drugs/DB05087
    ApprovedInvestigational

    [L41135] In July 2023, ganaxolone was also approved under the same brand name and for the same indication by the EMA.[L47636] … [L41130] It was approved under the brand name ZTALMY by the US FDA in March 2022 for the treatment of seizures associated with CDKL5 deficiency disorder (CDD), becoming the first FDA-approved treatment

  7. Drug

    Serelaxin

    go.drugbank.com/drugs/DB05794
    Investigational

    human relaxin is a hormone produced during pregnancy that facilitates the birth process by causing a softening and lengthening of the cervix and the pubic symphysis (the place where the pubic bones come

    Categories: Vasodilators Used in Cardiac Diseases
  8. Target

    NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 8

    go.drugbank.com/bio_entities/BE0000367
    TargetHumans

    Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis (PubMed:27626371, PubMed:32385911, PubMed:33153867). … Complex I functions in the transfer of electrons from NADH to the respiratory chain (PubMed:27626371). The immediate electron acceptor for the enzyme is believed to be ubiquinone (PubMed:27626371)

    Synonyms: Complex I-19kD, Complex I-PGIV
  9. Drug

    Efbemalenograstim alfa

    go.drugbank.com/drugs/DB18704
    ApprovedInvestigational

    This approval was contingent on positive results observed in two pivotal Phase 3 Studies GC-627-04 and GC-627-05 in the US and Europe respectively.[L48887] … [A33650,A262172] On November 22, 2023, efbemalenograstim alfa was approved by the FDA under the brand name Ryzneuta for the treatment of chemotherapy-induced neutropenia in adult patients with non-myeloid

    Synonyms: Rh g-csf fc fusion protein f-627, Recombinant dimeric g-csf fusion protein f627
  10. Drug

    Human calcitonin

    go.drugbank.com/drugs/DB06773
    Approved

    Calcitonin was first discovered in isolated parathyroid tissue as a substance with a serum-calcium-lowering effect. … [A32099] It is constituted as a 32-amino acid single chain polypeptide structure that gets secreted as a regulatory agent in calcium-phosphorus metabolism.